4//SEC Filing
REID OGDEN R 4
Accession 0001192482-06-000082
CIK 0001305409other
Filed
Feb 8, 7:00 PM ET
Accepted
Feb 9, 6:47 PM ET
Size
8.7 KB
Accession
0001192482-06-000082
Insider Transaction Report
Form 4
REID OGDEN R
Director
Transactions
- Conversion
Option to Purchase Series B Preferred Stock
2006-02-07−89,214→ 0 totalExercise: $0.00From: 2003-05-30Exp: 2007-05-30→ Common Stock (14,869 underlying) - Award
Option to Purchase Common Stock
2006-02-07+14,869→ 14,869 totalExercise: $4.35From: 2003-05-30Exp: 2007-05-30→ Common Stock (14,869 underlying)
Footnotes (4)
- [F1]This option was (is) granted to the reporting person by Corporate Opportunity Fund, L.P. and Corporate Opportunity Fund (Institutional), L.P., not the Issuer.
- [F2]There is no cost in connection with the conversion of the Option to Purchase Series B Preferred Stock of the Issuer into an Option to Purchase Common Stock of the Issuer.
- [F3]This number of shares represents the Common Stock Equivalent for the Preferred Stock which the reporting person has an Option to Purchase as of February 6, 2006; it also reflects a 1:6 reverse stock split which occurred on the Issuer's Common Stock on January 27, 2006. The conversion rate of the Derivative Securities is equal to (i) the stated value of the Derivative Securities ($.725 per share) divided by (ii) the conversion price for such Derivative Securities.
- [F4]This is an option grant for which there was no purchase price.
Documents
Issuer
Valera Pharmaceuticals Inc
CIK 0001305409
Entity typeother
Related Parties
1- filerCIK 0001018208
Filing Metadata
- Form type
- 4
- Filed
- Feb 8, 7:00 PM ET
- Accepted
- Feb 9, 6:47 PM ET
- Size
- 8.7 KB